63. MDR-TB: detection, prevalence, and drivers
Sunday, 06 December 2015, 12:15-13:15

Chair: Helen COX (South Africa)

Track: TB laboratory services: organisation and quality assurance

PC-1229-06  **Why MDR-TB patients do not accept treatment**
Z Xu, L Bai (*China*)

PC-1230-06  **RNTCP experience in rolling out base-line second-line drug susceptibility testing among MDR-TB cases**
M Ghedia, Ks Sachdeva, A Amar Shah, S Anand, P Parmar, R Ramachandran, A Sreenivas, F Sayyed Imran (*India*)

PC-1231-06  **Genetic characterization of multidrug-resistant Mycobacterium tuberculosis strains from various regions of Delhi**
J Arora, Z Sidiq, Manp Bhalla, P Visalakshi, Vith Myneedu, U Singh, D Behera, R Sarin (*India*)

PC-1232-06  **Multidrug-resistant tuberculosis among foreign-born persons in Japan**
N Kobayashi, T Hattori, T Kirikae, S Kato, J Suzuki, K Ohta (*Japan*)

PC-1233-06  **Drug-resistant tuberculosis and risk factors of multidrug resistance in Ukraine: results of the first nationwide survey**
E Pavlenko, A Barbova, A Hovhannesyan, Z Tsenilova, A Slavuckij, A Dean, M Dara, A Dadu (*Ukraine, Armenia, Switzerland, Denmark, Moldova*)

PC-1234-06  **Prevalence of MDR-TB and drug resistance patterns in retreatment cases in Punjab, Pakistan**
A Majeed, M Awais Arif, H Javed, S Kanwal (*Pakistan*)

PC-1235-06  **Estimating true MDR prevalence rates using routinely collected data**
Z Mclaren, R Burger (*USA*)

PC-1236-06  **Drug resistance patterns in MDR-TB patients: challenges for future regimen design**
H Stagg, J Brown, E Ibraim, V Riekstina, P Viiklepp, G Dravniece, C Jackson, P White (*UK, Estonia, Switzerland*)